| Outcome Measures: |
Primary: Change from baseline in clinical laboratory hematology tests., Week 2 and Months 6, 12, 18, and Final Visit|Change from baseline in clinical laboratory chemistry tests., Week 2 and Months 6, 12, 18, and Final Visit|Blood pressure measurements., All visits.|Pulse measurements., All visits.|Body weight., All visits.|Physical examinations., Months 6, 12, 18, and Final Visit|12-lead electrocardiogram., Months 6, 12, and Final Visit|Adverse event occurrence., All visits or at occurrence | Secondary: Change from baseline in glycosylated hemoglobin., Months 3, 6, 9, 12, 15, 18, 21, and Final Visit|Change from baseline in fasting plasma glucose., All visits.|Change from baseline in fasting insulin., Months 3, 6, 9, 12, 15, 18, 21, and Final Visit|Change from baseline in fasting C-peptide., Months 6, 12, 18, and Final Visit|Change from baseline in triglycerides., Months 6, 12, 18, and Final Visit|Change from baseline in total cholesterol., Months 6, 12, 18, and Final Visit|Change from baseline in high-density lipoprotein., Months 6, 12, 18, and Final Visit|Change from baseline in low-density lipoprotein., Months 6, 12, 18, and Final Visit|Change from baseline in very-low-density lipoprotein., Months 6, 12, 18, and Final Visit|Change from baseline in low-density lipoprotein fractionation., Months 6, 12, 18, and Final Visit|Change from baseline in intermediate-density lipoprotein size., Months 6, 12, 18, and Final Visit|Change from baseline in large low-density lipoprotein size., Months 6, 12, 18, and Final Visit|Change from baseline in small low-density lipoprotein size., Months 6, 12, 18, and Final Visit|Change from baseline in medium-small low-density lipoprotein size., Months 6, 12, 18, and Final Visit|Change from baseline in very-small low-density lipoprotein size., Months 6, 12, 18, and Final Visit|Change from baseline in mean low-density lipoprotein size., Months 6, 12, 18, and Final Visit|Change from baseline in apolipoproteins A1 and B., Months 12 and Final Visit|Change from baseline in atherosclerosis marker plasminogen activator inhibitor 1., Months 6, 12, and Final Visit|Change from baseline in atherosclerosis marker fibrinogen., Months 6, 12, and Final Visit|Change from baseline in inflammation marker Interleukin-6., Months 6, 12, and Final Visit|Change from baseline in inflammation marker C-reactive protein., Months 6, 12, and Final Visit
|
